(March 4, 2024, 2:51 PM EST) -- TRENTON, N.J. — A New Jersey appellate court on March 1 affirmed lower court decisions consolidated on appeal that dismissed similar qui tam suits filed against Bayer and Eli Lilly alleging that they violated the New Jersey False Claims Act (NJFCA) by participating in unlawful marketing schemes resulting in false claims being paid by government health care programs, finding that the complaints were appropriately dismissed under the NJFCA’s public disclosure bar....